H. pylori Treatment and Eradication — Overview

Getting rid of Helicobacter pylori is one of the most satisfying things medicine can do — a curable chronic infection that, left alone, quietly raises your lifetime risk of stomach ulcers and even stomach cancer. The catch is that H. pylori lives in a remarkably hostile place (the stomach lining) and has an impressive ability to develop resistance to antibiotics. For those reasons, eradication always involves a combination of drugs taken together, for long enough, with no missed doses. This overview explains the logic behind that approach, introduces the main drug regimens, covers the new acid blockers that are changing the field, and walks through what happens when a first attempt fails.

Table of Contents

  1. Why H. pylori Is Never Treated With One Antibiotic
  2. The Essential Role of Acid Suppression (PPIs)
  3. Overview of Available Regimens
  4. Vonoprazan — The New Acid Blocker
  5. Duration of Therapy: Why 14 Days Wins
  6. The Single Most Important Thing Patients Can Do
  7. Confirming Eradication — Test of Cure
  8. What to Do When Treatment Fails
  9. Deep-Dive Sub-Articles in This Section
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Why H. pylori Is Never Treated With One Antibiotic

When a single antibiotic is aimed at H. pylori, the results are poor — eradication rates below 50% in most studies. The bacteria are naturally resistant to many drug classes, and even to the antibiotics that should work, a small subpopulation of naturally resistant organisms can survive a solo course and repopulate the stomach within weeks.

Combination therapy tackles this in two ways. First, two antibiotics with different mechanisms of action are used simultaneously; a bacterium that survives one drug is still killed by the other. Second, acid suppression is added — H. pylori is far more vulnerable to antibiotics in a neutral pH environment than in the acidic stomach it normally inhabits. Raise the stomach pH to 5 or higher, and antibiotic concentrations in the gastric mucus rise substantially while the bacteria become more metabolically active (and therefore more antibiotic-susceptible).

This is not a theoretical concern. Studies consistently show that adding a proton pump inhibitor to a two-antibiotic regimen raises eradication rates by 10–20 percentage points compared with antibiotics alone.

The Essential Role of Acid Suppression (PPIs)

Proton pump inhibitors (PPIs) — omeprazole, lansoprazole, pantoprazole, esomeprazole, rabeprazole — are prescribed twice daily throughout every standard H. pylori regimen. They are not treating the infection directly; they are engineering a better environment for the antibiotics to work.

H. pylori burrows into the mucous layer of the stomach and divides relatively slowly. Acid keeps the bacteria in a near-dormant state and degrades many antibiotics (especially amoxicillin, which is most active at neutral pH) before they reach adequate tissue concentrations. By raising stomach pH above 6, twice-daily high-dose PPIs:

The choice of which PPI matters somewhat: rabeprazole and esomeprazole are less dependent on a liver enzyme (CYP2C19) that varies between individuals and can make standard-dose omeprazole less effective in "fast metabolizer" patients. In practice, doubling the PPI dose (e.g., omeprazole 40 mg twice daily rather than 20 mg) often compensates for this variability.

Overview of Available Regimens

Four main regimen families cover most real-world prescribing situations. The right choice depends on local antibiotic resistance rates, which your doctor should know for your region.

For a detailed breakdown of each regimen's doses, timing, and clinical evidence, see the Antibiotic Therapy sub-article.

Vonoprazan — The New Acid Blocker

Vonoprazan is a potassium-competitive acid blocker (P-CAB) — a newer class that suppresses stomach acid more powerfully, more quickly, and more consistently than PPIs. Where a PPI needs to bind to an actively secreting pump and takes several days to reach full effect, vonoprazan blocks the pump regardless of its secretory state and reaches maximum acid suppression within hours of the first dose.

In clinical trials, vonoprazan-based dual therapy (vonoprazan + amoxicillin) and triple therapy (vonoprazan + amoxicillin + clarithromycin) have matched or outperformed PPI-based regimens, with dual therapy achieving over 80% eradication even in clarithromycin-resistant strains in some Japanese trials. Vonoprazan is now approved in Japan and the United States (FDA approved in 2022 under the brand name Voquezna) and is increasingly used in Canada, South Korea, and parts of Europe.

For patients who have failed PPI-based regimens or who have clarithromycin resistance confirmed by testing, vonoprazan-based rescue therapy is a growing option. It is also more convenient — vonoprazan is dosed once daily rather than twice, which can improve adherence.

The main limitation is cost and availability: vonoprazan is still significantly more expensive than generic PPIs in markets where it is available, and it remains unavailable in many lower-income countries.

Duration of Therapy: Why 14 Days Outperforms 7–10 Days

A landmark 2017 meta-analysis pooling data from over 50 randomized trials found that 14-day courses of triple therapy raised eradication rates by roughly 5 percentage points over 10-day courses and nearly 10 percentage points over 7-day courses — a clinically meaningful difference when you are trying to cross the 90% eradication threshold that guidelines consider adequate.

The mechanism makes sense: H. pylori populations are not uniform. Some organisms are in slow-dividing states when therapy begins; a longer course catches them as they cycle back into active division. Shorter courses can leave a residual population that rebounds after treatment ends.

Most international guidelines (American College of Gastroenterology, European Helicobacter Study Group) now recommend 14 days as the standard duration for first-line therapy. Ten-day courses may be acceptable for bismuth quadruple therapy in regions with high metronidazole resistance, but the trend across all regimen types is toward longer treatment.

The practical implication: if your prescription is written for 7 days, it is reasonable to ask your doctor whether 14 days is appropriate for your situation — especially if you live in an area with known high clarithromycin resistance.

The Single Most Important Thing Patients Can Do: Finish the Full Course

Side effects are common with H. pylori regimens. The combination of two antibiotics and a PPI — sometimes plus bismuth — predictably causes nausea, a metallic taste, loose stools, and general GI upset in a significant minority of patients. Clarithromycin can cause a bitter taste so strong that patients describe it as tasting like chemicals. Bismuth turns stools black and can cause temporary darkening of the tongue.

None of these side effects are dangerous. All of them are temporary. The problem is that they lead many patients to stop early — and stopping H. pylori therapy early is worse than not starting it at all, because it selectively kills susceptible bacteria while leaving resistant ones to repopulate and potentially become permanently harder to eradicate.

Strategies that help patients complete treatment:

Confirming Eradication — Test of Cure

Completing treatment does not mean the infection is gone. Eradication rates even with optimal therapy are 85–95%, not 100%. A test of cure is essential to confirm the bacteria have been eliminated — particularly because untreated or incompletely treated H. pylori continues to damage the stomach lining silently.

Two non-invasive tests are recommended for confirming eradication:

Critical timing rule: both tests must be done at least 4 weeks after completing antibiotics and at least 2 weeks after stopping any PPI. PPIs suppress H. pylori's urease activity and can produce false-negative results if the test is done while the patient is still taking them. This timing is where many test-of-cure attempts go wrong — patients are sometimes tested while still on their PPI, receive a false-negative, and are incorrectly told they are cured.

Blood antibody tests are not appropriate for test of cure — antibodies persist for months to years after eradication and cannot confirm that the bacteria are gone.

What to Do When Treatment Fails

A failed course of H. pylori therapy is defined as a positive test of cure 4+ weeks after completing treatment. It happens in roughly 10–20% of first-line treatment attempts, most commonly because of antibiotic resistance — either pre-existing resistance that was not tested for, or resistance that emerged during the course.

The most important principle after failure: do not repeat the same regimen. The bacteria that survived are, by definition, resistant to at least one drug in the original combination. Repeating the same drugs is unlikely to succeed and risks consolidating resistance further.

Second-line options depend on what was used first:

Rifabutin-based rescue therapy (PPI + amoxicillin + rifabutin) is reserved for patients who have failed multiple prior regimens, as rifabutin resistance is rare but expensive to create. For full details on resistance mechanisms and rescue options, see the Antibiotic Resistance sub-article.

Deep-Dive Sub-Articles in This Section

This Treatments section covers H. pylori eradication in depth across four focused pages:

Key Research Papers

These peer-reviewed studies underpin the treatment recommendations described on this page. PMID links open the abstract on PubMed.

Back to Table of Contents

Connections

Back to Table of Contents